Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-73.90M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.43 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -43.95% |
| Return on Assets (Trailing 12 Months) | -42.94% |
| Current Ratio (Most Recent Fiscal Quarter) | 14.25 |
| Quick Ratio (Most Recent Fiscal Quarter) | 14.25 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.86 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.31 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.53 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.38 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 67.58M |
| Free Float | 67.03M |
| Market Capitalization | $82.44M |
| Average Volume (Last 20 Days) | 0.14M |
| Beta (Past 60 Months) | -0.12 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 69.76% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |